Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company TWi Pharmaceuticals Holding Inc.
DescriptionRecombinant disintegrin protein from snake venom
Molecular Target Integrin alpha(V)beta(3) (CD51/CD61)
Mechanism of ActionAngiogenesis inhibitor; Binds integrin alpha(v)beta(3)
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today